


LGALS3BP Antibody / Galectin-3-binding protein (FY13218)


Catalog No.	Formulation	Size
FY13218	Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml	100 ug

[Bulk quote request](#)


Availability	1-2 days
Species Reactivity	Human, Rat
Format	Lyophilized
Host	Rabbit
Clonality	Polyclonal (rabbit origin)
Isotype	Rabbit IgG
Purity	Immunogen affinity purified
Buffer	Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na ₂ HPO ₄ .
UniProt	Q08380
Applications	Western Blot : 0.25-0.5ug/ml Immunocytochemistry : 5ug/ml Immunofluorescence : 5ug/ml Flow Cytometry : 1-3ug/million cells ELISA : 0.1-0.5ug/ml
Limitations	This LGALS3BP antibody is available for research use only.



Immunofluorescent staining of LGALS3BP using anti-LGALS3BP antibody (green). LGALS3BP was detected in an immunocytochemical section of HELA cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 5 ug/ml rabbit anti-LGALS3BP antibody overnight at 4oC. DyLight 488 Conjugated Goat Anti-Rabbit IgG was used as secondary antibody at 1:500 dilution and incubated for 30 minutes at 37oC. The section was counterstained with DAPI nuclear stain (blue). Visualize using a fluorescence microscope and filter sets appropriate for the label used.



Western blot analysis of LGALS3BP using anti-LGALS3BP antibody. Lane 1: human HeLa whole cell lysates, Lane 2: human HepG2 whole cell lysates, Lane 3: human COLO 320 whole cell lysates, Lane 4: human 293T whole cell lysates, Lane 5: rat brain tissue lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-LGALS3BP antibody at 0.5 ug/ml overnight at 4oC, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal was developed using enhanced chemiluminescent. Western blot detection of LGALS3BP (Galectin-3-binding protein) shows a diffuse band pattern between ~70 and 90 kDa across multiple cell lines. Although the predicted mass is ~65 kDa, extensive N-glycosylation causes the mature secreted protein to migrate more slowly on SDS-PAGE.



Flow Cytometry analysis of HepG2 cells using anti-LGALS3BP antibody. Overlay histogram showing HepG2 cells stained with (Blue line). The cells were fixed with 4% paraformaldehyde and blocked with 10% normal goat serum. And then incubated with rabbit anti-LGALS3BP antibody (1 ug/million cells) for 30 min at 20oC. DyLight 488 conjugated goat anti-rabbit IgG (5-10 ug/million cells) was used as secondary antibody for 30 minutes at 20oC. Isotype control antibody (Green line) was rabbit IgG (1 ug/million cells) used under the same conditions. Unlabelled sample (Red line) was also used as a control.

Description

LGALS3BP antibody detects Galectin-3-binding protein, a secreted glycoprotein involved in cell adhesion, immune modulation, and tumor metastasis. The UniProt recommended name is Galectin-3-binding protein (LGALS3BP). Also known as 90K or Mac-2-binding protein, this multifunctional glycoprotein mediates extracellular interactions that influence immune cell communication, matrix remodeling, and viral infection processes.

Functionally, LGALS3BP antibody identifies a 585-amino-acid secreted protein characterized by a heavily glycosylated scavenger receptor cysteine-rich (SRCR)-like domain. LGALS3BP interacts with galectins, integrins, and extracellular matrix components such as fibronectin and laminin to facilitate cell adhesion and migration. It modulates immune signaling by promoting cytokine release, dendritic cell maturation, and macrophage activation. In the tumor microenvironment, LGALS3BP enhances metastatic potential by regulating cell-cell interactions and immune evasion mechanisms.

The LGALS3BP gene is located on chromosome 17q25.3 and is expressed in immune cells, epithelial tissues, and cancerous lesions. Its secretion increases in inflammatory conditions, viral infections, and malignancies, where it serves as a biomarker of immune activation and tumor progression.

Pathologically, elevated LGALS3BP levels have been associated with breast, prostate, and lung cancers, as well as HIV infection and autoimmune diseases. In cancer, high expression correlates with increased invasiveness and poor prognosis due to its roles in matrix remodeling and immune suppression. In infectious diseases, LGALS3BP can act as a host restriction factor that limits viral replication. Research using LGALS3BP antibody supports studies in cancer biology, immunology, and extracellular matrix signaling.

LGALS3BP antibody is validated for western blotting, immunohistochemistry, and ELISA to detect secreted glycoproteins. NSJ Bioreagents provides LGALS3BP antibody reagents optimized for research in tumor progression, immune signaling, and biomarker discovery.

Structurally, Galectin-3-binding protein forms disulfide-linked oligomers and contains multiple N-linked glycosylation sites critical for stability and receptor binding. Its SRCR-like domain mediates carbohydrate and protein interactions that

underpin its diverse functional roles. This antibody enables analysis of LGALS3BP's involvement in cell communication, matrix adhesion, and immune regulation.

Application Notes

Optimal dilution of the LGALS3BP antibody should be determined by the researcher.

Immunogen

E.coli-derived human LGALS3BP recombinant protein (Position: H115-K508) was used as the immunogen for the LGALS3BP antibody.

Storage

After reconstitution, the LGALS3BP antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.